Publications

Publications

Publications

A full list of of my publications can be found here: 

https://www.ncbi.nlm.nih.gov/sites/myncbi/1r9Zwxd-aq6QW/bibliography/public/

 

  1. Waterhouse BD and Navarra RL. The locus coeruleus-norepinephrine system and sensory signal processing: A historical review and current perspectives. Review. Brain Research. doi: 10.1016/j.brainres.2018.08.032, 2018.
  2. Navarra RL and Waterhouse BD. Considering noradrenergically mediated facilitation of sensory signal processing as a component of psychostimulant-induced performance enhancement. Review. Brain Research. doi: 10.1016/j.brainres.2018.06.027, 2018.
  3. Navarra RL, Clark BD, Garguilo AT, Waterhouse BD. Methylphenidate enhances early stage sensory processing and rodent performance of a visual signal detection task. Neuropsychopharmacology. 42(6):1326-1337, 2017.
  4. Navarra RL and Waterhouse BD. “What have we GANEd?” Application of a theoretical construct to explain experimental evidence for noradrenergic regulation of signal processing in sensory networks. – An invited commentary on “Norepinephrine ignites local hot spots of neuronal excitation: How arousal amplifies selectivity in perception and memory. Beh Brain Sciences. E219, doi: 10.1017/S0140525X15001909, 2016.
  5. Navarra RL, Clark BD, Zitnik GA, Waterhouse BD. Methylphenidate and atomoxetine enhance sensory-evoked neuronal activity in the visual thalamus of male rats. Exp Clin Psychopharmacol. 21(5):363-374, 2013.
  6. Malamas MS, Stange H, Schindler R, Lankau HJ, Grunwald C, Langen B, Egerland U, Hage T, Ni Y, Erdei J, Fan KY, Parris K, Marquis KL, Grauer S, Brennan J, Navarra R, Graf R, Harrison BL, Robichaud A, Kronbach T, Pangalos MN, Brandon NJ, Hoefgen N.  Novel triazines as potent and selective phosphodiesterase 10A inhibitors. Bioorg Med Chem Lett. 22(18):5876-84, 2012.
  7. Malamas MS, Ni Y, Erdei J, Stange H, Schindler R, Lankau HJ, Grunwald C, Fan KY, Parris K, Langen B, Egerland U, Hage T, Marquis KL, Grauer S, Brennan J, Navarra R, Graf R, Harrison BL, Robichaud A, Kronbach T, Pangalos MN, Hoefgen N, Brandon NJ.  Highly potent, selective, and orally active phosphodiesterase 10A inhibitors. J Med Chem. 54(21):7621-38, 2011.
  8. Marquis KL, Comery TA, Jow F, Navarra RL, Grauer SM, Pulicicchio C, Kelley C, Brennan JA, Roncarati R, Scali C, Haydar S, Ghiron C, Terstappen GC, Dunlop J.  Preclinical assessment of adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology, 218(4):635-47, 2011. 
  9. Kelly MP, Logue SF, Brennan J, Lakkaraju S, Jiang L, Rizzo S, Platt BJ, Dwyer JM, Neal S, Pulito VL, Agostino MJ, Grauer S, Navarra RL, Kelley C, Comery TA, Marquis K, Murrills RJ, Brandon NJ.  PDE11A expression in the brain is enriched in ventral hippocampus and deletion results in schizophrenia-releated phenotypes.  PNAS, 107(18):8457-62, 2010.
  10. Brennan JA, Graf R, Grauer SM, Navarra RL, Pulicicchio CM, Hughes ZA, Lin Q, Wantuch C, Rosenzweig-Lipson S, Pruthi F, Lai M, Smith D, Goutier W, van de Neut M, Robichaud AJ, Rotella D, Feenstra RW, Kruse C, Broqua P, Beyer CE, McCreary AC, Pausch MH and Marquis KL (2009) WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]:  a novel dopamine D2 receptor partial agonist / serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity.  Journal of Pharmacology and Experimental Therapeutics, 332(1): 190-201, 2010.
  11. Rotella DP, McFarlane GR, Greenfield A, Grosanu C, Robichaud AJ, Denny RA, Feenstra RW, Núñez-García S, Reinders JH, Neut M, McCreary A, Kruse CG, Sullivan K, Pruthi F, Lai M, Zhang J, Kowal DM, Carrick T, Grauer SM, Navarra RL, Graf R, Brennan J, Marquis KL, Pausch MH. Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorganic & Medicinal Chemistry Letters, 19(19):5552-5, 2009.
  12. Grauer SM, Pulito VL, Navarra R, Kelly M, Kelley C, Graf R, Langen B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F, Marquis K, Malamas M, Hage T, Comery TA, Brandon NJ.  PDE10A Inhibitors show anti-psychotic, pro-cognitive and negative symptom activities suggesting broad-spectrum utility for the treatment of schizophrenia.  Journal of Pharmacology and Experimental Therapeutics, 331(2):574-590, 2009.
  13. Grauer SM, Graf R, Navarra R, Sung A. Logue SF, Stack G, Huselton C, Liu Z, Comery TA, Marquis KL, Rosenzweig-Lipson S. WAY-163909, a 5-HT2C agonist, enhances the preclinical potency of current antipsychotics. Psychopharmacology, 204(1):37-48, 2009.
  14. Liu F, Grauer S, Kelley, C, Navarra R, Graf R, Zhang G, Day M, Gilbert A, Brandon N, Rosenzweig-Lipson S, Marquis K.  ADX-47273: A novel metabotropic glutamate receptor 5 selective positive allosteric modulator has preclinical antipsychotic-like and pro-cognitive activities.  Journal of Pharmacolology and Experimental Therapeutics, 327(3):827-39, 2008.
  15. Liu F, Day M, Muniz L, Bitran D, Revilla-Sanchez R, Grauer S, Sung A, Navarra R, Reinhart P, Marquis K, Moss S, Pangalos M, Brandon N.  Activation of estrogen receptor beta regulates hippocampus synaptic plasticity and improves memory.  Nature Neuroscience, 11(3):334-43, 2008.
  16. Navarra R, Comery TA, Graf R, Rosenzweig-Lipson S, Day M.  5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test.  Behavioural Brain Research: 188(2):412-5, 2008.
  17. Navarra R, Graf R, Huang Y, Logue S, Comery T, Day M. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test.  Progress in Neuro-pharmacology & Biological Psychiatry, 32(1):334-41, 2008.
  18. Day M, Pan, JB, Buckley MJ, Cronin E, Hollingsworth PR, Hirst WD, Navarra R, Sullivan JP, Decker MW, Fox GB. Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test.  Biochemical Pharmacology, 73(8)1123-34, 2007.